Altered strain of the modified vaccinia virus ankara (mva)
CA 2397675 C · Owner: Bavarian Nordic A/S · Inventors: Mayr, Anton
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides new strains of the Modified Vaccinia Virus Ankara (MVA) that have a strongly reduced virulence for most mammals especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine. The invention also provides a method for producing said adapted MVA strains. The adapted MVA can be used e.g. for parenteral immunization as a vector system, or in the active , or inactivated from as an adjuvant or as a regulator of the unspecific components of the immune system.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 10, 2001 and granted November 13, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 10, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 10, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.